Legend Biotech | 6-K: Legend Biotech Announces EU Commission Approval of CARVYKTI for Second-Line Treatment in Patients with Relapsed or Refractory Multiple Myeloma
Apr 23 01:11
Legend Biotech | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
Apr 16 19:34
Legend Biotech | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
Apr 8 19:07
Legend Biotech | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-BlackRock, Inc.(3.0%)
Apr 6 00:25
Legend Biotech | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
Mar 29 20:02
Legend Biotech | 144: Notice of proposed sale of securities pursuant to Rule 144
Mar 29 04:32
Legend Biotech | 144: Notice of proposed sale of securities pursuant to Rule 144
Mar 28 04:20
Legend Biotech | 144: Notice of proposed sale of securities pursuant to Rule 144
Mar 27 05:26
Legend Biotech | 144: Notice of proposed sale of securities pursuant to Rule 144
Mar 26 05:00
Legend Biotech | 144: Notice of proposed sale of securities pursuant to Rule 144
Mar 26 04:36
Legend Biotech | 144: Notice of proposed sale of securities pursuant to Rule 144
Mar 19 23:11
Legend Biotech | F-3ASR: Automatic shelf registration statement of securities of well-known seasoned issuers
Mar 19 20:01
Legend Biotech | 20-F: Registration statement / Annual report / Transition report
Mar 19 19:06
Legend Biotech | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
Mar 16 03:21
Legend Biotech | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
Mar 13 20:38
Legend Biotech | 6-K: Report of foreign private issuer (related to financial reporting)
Mar 11 19:56
Legend Biotech | 144: Notice of proposed sale of securities pursuant to Rule 144
Feb 29 11:21
Legend Biotech | 144/A: Others
Feb 29 07:49
Legend Biotech | 144: Notice of proposed sale of securities pursuant to Rule 144
Feb 28 08:52
Legend Biotech | 144: Notice of proposed sale of securities pursuant to Rule 144
Feb 24 02:15
No Data
No Data